Shaquille O'Neal disclosed in 2025 that he was taking a GLP-1 medication — specifically Zepbound (tirzepatide) — to treat obstructive sleep apnea (OSA), a condition he said had been diagnosed through a sleep study at a Harvard-affiliated lab after he retired from the NBA in 2011.^[1] The framing matters, and the coverage that treats his disclosure as another celebrity weight-loss story is misreading what he actually said. This is a celebrity sleep-disorder story that happens to intersect with a drug class better known for a different indication.

Why the indication is significant

Tirzepatide, in addition to its earlier FDA-approved indications for type 2 diabetes and chronic weight management, received an FDA-approved indication for the treatment of moderate-to-severe obstructive sleep apnea in adults with obesity. O'Neal's disclosure tracks that specific indication — a diagnosed clinical condition, treated with a labeled medication for that condition — rather than the chronic-weight-management indication that has dominated public coverage of the drug class.

OSA is a common, under-diagnosed, and clinically consequential condition. It is associated with elevated cardiovascular risk, daytime sleepiness with measurable safety implications, and worsened outcomes across a range of comorbid conditions. Its association with obesity is well-characterized, and the mechanism through which weight reduction improves OSA — reduction in upper-airway soft-tissue loading — is well-established. That is the clinical context inside which O'Neal's disclosure sits.

The commercial relationship

O'Neal is the face of an Eli Lilly Zepbound advertising campaign, a paid commercial relationship that is part of the public record of his disclosure and is disclosed as such by the reporting that has covered it.^[1] As with the Serena Williams profile in this section, that commercial layer does not invalidate the underlying medical account, but it belongs alongside it. Readers evaluating the disclosure are best served by holding both facts in the same frame.

His own framing of the treatment

O'Neal has publicly stressed that the medication is one component of his OSA treatment, alongside 'eating right and staying active.'^[1] That framing is consistent with how the prescribing label and major medical organizations describe the drug's role — pharmacotherapy as an adjunct to, not a replacement for, the lifestyle and medical management that patients with obesity-related conditions typically require. The lifestyle-plus-medication framing is unglamorous, which is one reason it tends to get compressed out of shorter coverage.

What the SURMOUNT-OSA trial actually measured

The FDA's obstructive-sleep-apnea indication for tirzepatide rests on the SURMOUNT-OSA program: two phase III randomized trials in adults with moderate-to-severe OSA and obesity, published in the New England Journal of Medicine in 2024. The trials measured the apnea-hypopnea index — the standard polysomnographic count of breathing disturbances per hour of sleep — and also collected patient-reported outcomes, including a validated measure of sleep-related impairment.^[2] Participants receiving tirzepatide reported reductions in sleep-related impairment relative to placebo alongside the AHI reduction. That is the trial-level evidence the FDA drew on for the indication, and it is the clinical context inside which O'Neal's disclosure sits.

What the profile is trying to make visible

Two things are worth foregrounding for Half-Life's readers. First, the same drug class can carry very different clinical stories depending on the indication, and the OSA story is meaningfully distinct from the general weight-management story that has dominated coverage. Second, the presence of a paid endorsement relationship is a factual disclosure that belongs in any responsible account, without being treated as automatic disqualification of the personal report.

The regulatory frame, briefly

Zepbound is the brand name for tirzepatide as approved by the FDA. Prescriptions are written by licensed clinicians and filled by licensed pharmacies. This profile describes activity inside the approved-drug regulatory system and does not overlap with the research-peptide topics covered elsewhere on the site.